The specificity of this peptide was confirmed in vitro by testing the cytotoxic activity of breast cancer cells overexpressing CCR5, a major CCL8 receptor, and by a neutralizing anti‐CCL8 antibody we developed. The gene discussed is CCL8; the disease is breast cancer.